Large Volume Wearable Injectors Market by Type of Device, Usability, Therapeutic Area, Key Geographical Regions - Global Industry Trends and Forecasts, 2021-2035 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Large Volume Wearable Injectors Market by Type of Device, Usability, Therapeutic Area, Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035" report has been added to ResearchAndMarkets.com's offering.

The "Large Volume Wearable Injectors Market" report features an extensive study of the current market landscape and the likely future evolution of these self-injection devices, over the next fifteen years.

It specifically lays emphasis on the emergence of patient-centric, convenient, cost-effective and user-friendly wearable drug delivery solutions that are capable of administering large volumes of a drug subcutaneously, in the home-care setting.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for large volume wearable injectors. Based on parameters, such as the number of commercialized devices, number of devices under development, price of the device and the annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2021-2035.

Over the last few years, the industry has seen the emergence of advanced drug delivery devices, such as wearable injectors, autoinjectors and pen injectors. These are the self-injection devices that have the capability of producing a sustained therapeutic effect, thereby improving patient adherence and efficacy of treatments. Such practices also allow reductions in costs and enable the optimal usage of healthcare resources.

The approval of novel drugs, specifically biologics that have high viscosity and cannot be administered in lower volume, has further led to an increased demand for advanced drug delivery devices. As a result, medical device industry has come up with several large volume wearable injectors suitable for the delivery of such molecules. These innovative injection systems offer numerous dosing options (basal, bolus or continuous), integrated safety mechanisms, along with minimal or no risk of needlestick injuries.

Key Questions Answered

• Who are the leading large volume wearable device developers?
• Which are the popular types of wearable devices available in this market?
• What are the key challenges faced by stakeholders engaged in the development of large volume wearable injectors?
• What types of partnership models are commonly being adopted by stakeholders in this industry?
• Who are the key investors in this domain?
• How has the intellectual property landscape of wearable injectors evolved over the years?
• Which drug candidates are likely to be considered for administration via wearable injectors?
• What factors are likely to influence the evolution of this market?
• Which geographies are the most active in conducting clinical trials on large volume drug device combinations?
• How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview

3.2. Overview of Drug Delivery Devices

3.3. Conventional Parenteral Drug Delivery Devices

3.3.1 Limitations of Conventional Parenteral Drug Delivery Devices

3.3.2 Needlestick Injuries

3.3.2.1. Incidence and Cost Burden

3.3.2.2. Prevention of Needlestick Injuries

3.3.2.3. Government Legislations for the Prevention of Needlestick Injuries

3.4. Emergence of Self-Administration Devices

3.4.1. Driving Factors

3.4.1.1. Rising Burden of Chronic Diseases

3.4.1.2. Healthcare Cost Savings

3.4.1.3. Need for Immediate Treatment in Emergency Situations

3.4.1.4. Growing Injectable Drugs Market

3.4.1.5. Need for Improving Medication Adherence

3.5. Available Self-Injection Devices

3.5.1. Prefilled Syringes

3.5.2. Pen-Injectors

3.5.3. Needle-Free Injectors

3.5.4. Autoinjectors

3.5.5. Large Volume Wearable Injectors

3.6. Regulatory Considerations

3.6.1. Medical Devices

3.6.2. Drug Device Combination Products

3.7. Future Perspectives

4. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

4.1. Chapter Overview

4.2. Large Volume Wearable Injectors: Overall Market Landscape

4.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape

4.4. Large Volume Wearable Injectors for Non-Insulin Drugs: Developer Landscape

5. LARGE VOLUME DRUG DEVICE COMBINATIONS: CURRENT MARKET LANDSCAPE

5.1. Chapter Overview

5.2. Large Volume Drug Device Combinations: Market Landscape

5.3 Large Volume Drug Device Combinations: Developer Landscape

6. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN DRUGS: CURRENT MARKET LANDSCAPE

6.1. Chapter Overview

6.2. Large Volume Wearable Injectors for Insulin Drugs: Market Landscape

6.3. Large Volume Wearable Injectors for Insulin Drugs: Developer Landscape

7. PRODUCT COMPETITIVENESS ANALYSIS

7.1. Chapter Overview

7.2. Methodology

7.3. Assumptions / Key Parameters

7.4. Product Competitiveness Analysis

8. LARGE VOLUME WEARABLE INJECTORS: COMPANY PROFILES

8.1. Chapter Overview

8.2. Large Volume Wearable Injectors for Non-Insulin Drugs: Key Players

8.2.1. Becton Dickinson

8.2.2. Bespak

8.2.3. Enable Injections

8.2.4. Insulet

8.2.5. Roche

8.2.6. Sensile Medical

8.2.7. Sonceboz

8.2.8. SteadyMed Therapeutics

8.2.9. Weibel CDS

8.2.10. West Pharmaceutical Services

8.3. Large Volume Wearable Injectors for Insulin Drugs: Key Players

8.3.1. CeQur

8.3.2. Debiotech

8.3.3. Eli Lilly

8.3.4. Medtronic

8.3.5. PharmaSens

8.3.6. SOOIL Development

8.3.7. Tandem Diabetes Care

9. DRUG-DEVICE COMBINATIONS: TABULATED PROFILES

9.1. Chapter Overview

9.2. 3MT hMTS (Adalimumab)

9.3. D-mine Pump (Apomorphine)

9.4. ND0701 (Apomorphine)

9.5. SMT-301 (Bupivacaine)

9.6. sc2Wear Infusor (Ceftriaxone)

9.7. 3 mL Micropump (Furosemide)

9.8. FUROSCIX On-body Infusor (Furosemide)

9.9. Herceptin sc Injection (Herceptin)

9.10. SMT-201(Ketorolac)

9.11. ND0612 and ND0901 (Levodopa and Carbidopa)

9.12. The LUTREPULSE System (Lutrepulse)

9.13. Neulasta OnProT On-body Injector (Neulasta)

9.14. Pushtronex System (Repatha)

9.15. ULTOMRIS (Ravulizumab)

9.16. Trevyent (Treprostinil)

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview

10.2. Partnership Models

10.3. List of Partnerships and Collaborations

11. KEY ACQUISITION TARGETS

11.1. Chapter Overview

11.2. Scope and Methodology

11.3. Scoring Criteria and Key Assumptions

11.4. Potential Acquisition Targets for Players Offering Non-Insulin Drug Delivery Players

11.5. Potential Acquisition Targets for Players Offering Insulin Drug Delivery Players

11.6. Concluding Remarks

12. PATENT ANALYSIS

12.1. Chapter Overview

12.2. Scope and Methodology

12.3. Large Volume Wearable Injectors: Patent Analysis

12.4. Large Volume Wearable Injectors: Benchmarking Patent Analysis

13. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

13.1. Chapter Overview

13.2. Marketed Drugs

13.3. Clinical stage Drug Candidates

13.4. Small Molecules

14. CLINICAL TRIAL ANALYSIS

14.1. Chapter Overview

14.2. Scope and Methodology

14.3. Large Volume Wearable Injectors: Clinical Trial Analysis

15. FUNDING AND INVESTMENT ANALYSIS

15.1. Chapter Overview

15.2. Types of Funding

15.3. Large Volume Wearable Injectors: Recent Funding Instances

16. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN

16.1. Chapter Overview

16.2. Device Development Supply Chain

16.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development

16.4. List of CMOs

16.5 Medical Device: Product Design and Development

17. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

17.1. Chapter Overview

17.2. General Regulatory and Reimbursement Guidelines for Medical Devices

18. MARKET SIZING AND OPPORTUNITY ANALYSIS

18.1. Chapter Overview

18.2. Forecast Methodology and Key Assumptions

18.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Value)

19. SWOT ANALYSIS

19.1. Chapter Overview

19.2. SWOT Analysis

19.3. Large Volume Wearable Injectors: Future Growth Opportunities

19.3.1. Rising Focus on Self-Administration of Drugs

19.3.2. Possibility of Integration with Mobile Applications

19.3.3. Potential Life Cycle Management Tool

19.3.4. Potential Usability for Multiple Therapeutic Areas

20. EXECUTIVE INSIGHTS

20.1. Chapter Overview

20.2. Medipacs

20.3. Enable Injections

20.4. Subcuject

20.5. scPharmaceuticals

20.6. Elcam Medical

20.7. West Pharmaceutical Services

20.8. Ypsomed

20.9. Debiotech

20.10. Sorrel Medical

21. CONCLUDING REMARKS

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/5ooevf

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900